25 May 2013
Keywords: daclizumab, impresses, ph, ii, ms, study, biogen
Article | 19 March 2007
Biogen Idec and fellow USA-based PDL BioPharma say that data from an ongoing trial of the co-developed monoclonal antibody, daclizumab,
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
12 March 2007
5 March 2007
24 May 2013
© 2013 thepharmaletter.com